Back
|
Cell No. : Cell Name
RCB1104 : ψCRIP-MFGhM-CSF update : 2023/08/08 |
||||
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human M-CSF. Long term culture results in decrease of virus production. | |||
| Comment from the depositor | ||||
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. | |||
| Remarks | ||||
| Order Form | Order Form(C-0005.pdf) MTA(C-0007.pdf) MTA(C-0007p.pdf) | |||
| Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp). | ||||
| Basic information | Depositor | Hamada, Hirofumi | ||
| Originator | Hamada, Hirofumi | |||
| Year of deposit | 1994 | |||
| Original cell | ψCRIP | |||
| Animal | _mouse < Mammals | |||
| Strain name | NIH Swiss | |||
| Genus | Mus musculus | |||
| Species | mus domesticus | |||
| Age at sampling | embryo | |||
| Tissue | embryo | |||
| Classification | transformed | |||
| Recombinant | recombinant | |||
| Exogene | Amp^r, Human M-CSF cDNA | |||
| Recombinant virus | Yes | |||
| Lifespan | infinite | |||
| Morphology | fibroblast-like | |||
| BSL | BSL2 | |||
| Cellosaurus(Expasy) | CVCL_T385 | |||
| Medium | Medium List | |||
| Culture type | Adherent cells | |||
| Culture medium | DMEM (low glucose) + 10% CS | |||
| Antibiotics | Free | |||
| Passage method | 0.25% Trypsin | |||
| Culture information | Passage ratio | 1 : 4 split | ||
| SC frequency | Subculture : 1-2 times/week, Medium Renewal : 2 times/week | |||
| Temperature | 37 ℃ | |||
| CO2 concentration | 5 % | |||
| Freeze medium | Medium + 10% DMSO | |||
| Freezing method | Slow freezing | |||
| Mycoplasma/Acholeplasma | (-) | |||
| SSLP(mouse) | OK | |||
| Isozyme | LD, NP | |||
| Reference information | Reference | 3 | ||
| User's Publication | 1 | |||
Top
| Reference |
| 3686 Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 1996 56(8):1828-33 PubMed ID: 8620500 |
| 2174 Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan, R C Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993 90:3539-43 PubMed ID: 8097319 DOI: 10.1073/pnas.90.8.3539 |
| 2172 Danos O, Mulligan, R C Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A 1988 85:6460-4 PubMed ID: 3413107 DOI: 10.1073/pnas.85.17.6460 |
Top
| User's Publication |
| 2530 Ding LH, Iimura E, Saijo K, Hamada H, Ohno T. A speedy method to detect inserted DNA fragment in cell lines transfected with retroviral vectors. Cytotechnology 2000 34(3):243-52 PubMed ID: 19003400 DOI: 10.1023/A:1008187310534 |
Back
CELL BANK Website